Key statistics
On Friday, Black Diamond Therapeutics Inc (BDTX:NSQ) closed at 4.76, -37.86% below its 52-week high of 7.66, set on May 06, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.78 |
---|---|
High | 4.83 |
Low | 4.55 |
Bid | 4.67 |
Offer | 4.80 |
Previous close | 4.78 |
Average volume | 685.88k |
---|---|
Shares outstanding | 56.50m |
Free float | 55.19m |
P/E (TTM) | -- |
Market cap | 268.96m USD |
EPS (TTM) | -1.54 USD |
Data delayed at least 15 minutes, as of Sep 20 2024 21:00 BST.
More ▼
- Black Diamond Therapeutics to Host Webcast Presentation of Initial Phase 2 BDTX-1535 Data in Patients With Recurrent EGFRm NSCLC
- Black Diamond Therapeutics Presents Real-World Treatment Practices and Patient Outcomes in Newly Diagnosed NSCLC Patients with Non-Classical Mutations at the European Society for Medical Oncology (ESMO) Congress 2024
- Black Diamond Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics Presents Promising BDTX-1535 Clinical Data in Patients with Recurrent Glioblastoma at 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Black Diamond Therapeutics to Participate in Jefferies Global Healthcare Conference
- Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
- Black Diamond Therapeutics Announces Presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
- Black Diamond Therapeutics Announces Changes to Board of Directors
- Black Diamond Therapeutics Presents Novel Real-World Evidence of the Evolving EGFR Mutation Landscape in NSCLC and the Opportunity for BDTX-1535 in an Oral Presentation at the 2024 American Association of Cancer Research Annual Meeting
- Black Diamond Therapeutics to Participate in Upcoming Investor Conferences
More ▼